Gerrit Frommeyer1, Dirk G Dechering2, Sven Zumhagen2, Andreas Löher3, Julia Köbe2, Lars Eckardt2, Florian Reinke2. 1. Division of Electrophysiology, Department of Cardiovascular Medicine, University of Münster, Münster, Germany. Gerrit.Frommeyer@ukmuenster.de. 2. Division of Electrophysiology, Department of Cardiovascular Medicine, University of Münster, Münster, Germany. 3. Division of Cardiac Surgery, Department of Cardiothoracic Surgery, University of Münster, Münster, Germany.
Abstract
BACKGROUND: The totally subcutaneous implantable defibrillator (S-ICD) was introduced as a new alternative to conventional implantable defibrillators and is employed worldwide. This system is especially attractive for young patients. However, in patients with hypertrophic cardiomyopathy (HCM), T-wave oversensing may occur. To address the question whether the S-ICD system is suitable for HCM patients, the data of a standard of care prospective single-center S-ICD registry were evaluated. METHODS AND RESULTS: In the present study, 18 HCM patients who received an S-ICD for primary (n = 14) or secondary prevention (n = 4) and a minimal follow-up duration of 6 months were analyzed. The mean follow-up duration was 31.7 ± 15.4 months. Ventricular arrhythmias were adequately detected in 4 patients (22%). In 7 patients (39%), T-wave oversensing was noticed and led to at least one inappropriate shock in 4 patients (22%). Further adverse events included surgical revision due to a mobile sensing electrode and resulting noise detection as well as one case of early battery failure requiring pulse generator change. CONCLUSION: Patients with HCM and S-ICD systems have an increased risk of T-wave oversensing and inappropriate shock delivery. Thorough monitoring as well as exercise tests may help to improve device settings and thereby prevent T-wave oversensing.
BACKGROUND: The totally subcutaneous implantable defibrillator (S-ICD) was introduced as a new alternative to conventional implantable defibrillators and is employed worldwide. This system is especially attractive for young patients. However, in patients with hypertrophic cardiomyopathy (HCM), T-wave oversensing may occur. To address the question whether the S-ICD system is suitable for HCM patients, the data of a standard of care prospective single-center S-ICD registry were evaluated. METHODS AND RESULTS: In the present study, 18 HCM patients who received an S-ICD for primary (n = 14) or secondary prevention (n = 4) and a minimal follow-up duration of 6 months were analyzed. The mean follow-up duration was 31.7 ± 15.4 months. Ventricular arrhythmias were adequately detected in 4 patients (22%). In 7 patients (39%), T-wave oversensing was noticed and led to at least one inappropriate shock in 4 patients (22%). Further adverse events included surgical revision due to a mobile sensing electrode and resulting noise detection as well as one case of early battery failure requiring pulse generator change. CONCLUSION:Patients with HCM and S-ICD systems have an increased risk of T-wave oversensing and inappropriate shock delivery. Thorough monitoring as well as exercise tests may help to improve device settings and thereby prevent T-wave oversensing.
Authors: Gerrit Frommeyer; Dirk G Dechering; Sven Zumhagen; Julia Köbe; Lars Eckardt; Florian Reinke Journal: Clin Res Cardiol Date: 2015-07-07 Impact factor: 5.460
Authors: Raul Weiss; Bradley P Knight; Michael R Gold; Angel R Leon; John M Herre; Margaret Hood; Mayer Rashtian; Mark Kremers; Ian Crozier; Kerry L Lee; Warren Smith; Martin C Burke Journal: Circulation Date: 2013-08-27 Impact factor: 29.690
Authors: Amy J Brisben; Martin C Burke; Bradley P Knight; Stephen J Hahn; Keith L Herrmann; Venugopal Allavatam; Deepa Mahajan; Rick Sanghera; Michael R Gold Journal: J Cardiovasc Electrophysiol Date: 2015-02-17
Authors: Tobias Bobinger; Bernd Kallmünzer; Markus Kopp; Natalia Kurka; Martin Arnold; Max-Josef Hilz; Hagen B Huttner; Stefan Schwab; Martin Köhrmann Journal: Clin Res Cardiol Date: 2015-02-25 Impact factor: 5.460
Authors: Louise R A Olde Nordkamp; Joppe L F Warnaars; Kirsten M Kooiman; Joris R de Groot; Boudewijn R A M Rosenmöller; Arthur A M Wilde; Reinoud E Knops Journal: J Cardiovasc Electrophysiol Date: 2014-01-07
Authors: Andrew S Flett; Viviana Maestrini; Don Milliken; Mariana Fontana; Thomas A Treibel; Rami Harb; Daniel M Sado; Giovanni Quarta; Anna Herrey; James Sneddon; Perry Elliott; William McKenna; James C Moon Journal: Int J Cardiol Date: 2015-01-27 Impact factor: 4.164
Authors: Gerrit Frommeyer; Florian Reinke; Dietrich Andresen; Thomas Kleemann; Stefan G Spitzer; Joachim Jehle; Johannes Brachmann; Christoph Stellbrink; Matthias Hochadel; Jochen Senges; Lars Eckardt Journal: Clin Res Cardiol Date: 2019-07-31 Impact factor: 5.460
Authors: Nelson Wang; Ashleigh Xie; Richard Tjahjono; David H Tian; Steven Phan; Tristan D Yan; Pietro Bajona; Kevin Phan Journal: Ann Cardiothorac Surg Date: 2017-07
Authors: Julia Köbe; Katharina Hucklenbroich; Nils Geisendörfer; Markus Bettin; Gerrit Frommeyer; Florian Reinke; Dirk Dechering; Markus Burgmer; Lars Eckardt Journal: Clin Res Cardiol Date: 2016-11-22 Impact factor: 5.460
Authors: Vincent C Thomas; Mark Peterson; Martin McDaniel; Humberto Restrepo; Abraham Rothman; Amit Jain Journal: Pediatr Cardiol Date: 2017-05-22 Impact factor: 1.655
Authors: Tobias Schupp; Ibrahim Akin; Linda Reiser; Armin Bollow; Gabriel Taton; Thomas Reichelt; Dominik Ellguth; Niko Engelke; Uzair Ansari; Kambis Mashayekhi; Christel Weiß; Christoph Nienaber; Muharrem Akin; Martin Borggrefe; Michael Behnes Journal: Clin Res Cardiol Date: 2019-02-12 Impact factor: 5.460
Authors: Leon Dinshaw; Julia Münch; Jannis Dickow; Susanne Lezius; Stephan Willems; Boris A Hoffmann; Monica Patten Journal: Clin Res Cardiol Date: 2017-09-30 Impact factor: 5.460